• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Lifshitz Law PLLC Announces Investigations of BG, KDNY, QUOT, and DICE

    6/24/23 8:11:00 PM ET
    $BG
    $DICE
    $KDNY
    $QUOT
    Packaged Foods
    Consumer Staples
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BG alert in real time by email

    NEW YORK, June 24, 2023 (GLOBE NEWSWIRE) --

    Bunge Limited (NYSE:BG)

    Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of BG and Viterra Limited. Under the terms of the agreement, Viterra Limited shareholders will receive approximately 65.6 million shares of BG common stock and $2.0 billion in cash. In addition, BG will assume $9.8 billion of Viterra Limited debt and BG plans to repurchase $2.0 billion of BG common stock.

    If you are a BG investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

    Chinook Therapeutics, Inc. (NASDAQ:KDNY)

    Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of KDNY to Novartis AG for $40.00 per share in cash, plus a CVR of up to $4.00 per share payable upon the achievement of certain future regulatory milestones with respect to its lead product candidate, atrasentan.

    If you are a KDNY investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

    Quotient Technology, Inc. (NYSE:QUOT)

    Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of QUOT to Neptune Retail Solutions for $4.00 per share in cash.

    If you are a QUOT investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

    DICE Therapeutics, Inc. (NASDAQ:DICE)

    Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of DICE to Eli Lilly & Co. for $48.00 per share in cash.

    If you are a DICE investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

    ATTORNEY ADVERTISING.© 2023 Lifshitz Law PLLC. The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

    Contact:

    Joshua M. Lifshitz, Esq.

    Lifshitz Law PLLC

    Phone: 516-493-9780

    Facsimile: 516-280-7376

    Email: [email protected]



    Get the next $BG alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BG
    $DICE
    $KDNY
    $QUOT

    CompanyDatePrice TargetRatingAnalyst
    Bunge Limited
    $BG
    1/21/2025$115.00 → $95.00Overweight → Equal Weight
    Barclays
    Bunge Limited
    $BG
    8/1/2024$125.00 → $114.00Buy → Neutral
    Citigroup
    Bunge Limited
    $BG
    2/9/2024$122.00 → $105.00Hold → Buy
    HSBC Securities
    Bunge Limited
    $BG
    2/1/2024$108.00Buy
    Citigroup
    Bunge Limited
    $BG
    1/10/2024Outperform → Peer Perform
    Wolfe Research
    Bunge Limited
    $BG
    9/15/2023$122.00Hold
    HSBC Securities
    Chinook Therapeutics Inc.
    $KDNY
    8/8/2023$42.00Outperform → Neutral
    Wedbush
    Bunge Limited
    $BG
    6/22/2023$138.00Buy
    ROTH MKM
    More analyst ratings

    $BG
    $DICE
    $KDNY
    $QUOT
    SEC Filings

    See more
    • SEC Form S-4 filed by Bunge Limited

      S-4 - Bunge Global SA (0001996862) (Filer)

      7/10/25 4:17:42 PM ET
      $BG
      Packaged Foods
      Consumer Staples
    • SEC Form S-3ASR filed by Bunge Limited

      S-3ASR - Bunge Global SA (0001996862) (Filer)

      7/10/25 4:15:51 PM ET
      $BG
      Packaged Foods
      Consumer Staples
    • SEC Form SCHEDULE 13D filed by Bunge Limited

      SCHEDULE 13D - Bunge Global SA (0001996862) (Subject)

      7/8/25 6:00:59 PM ET
      $BG
      Packaged Foods
      Consumer Staples

    $BG
    $DICE
    $KDNY
    $QUOT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bunge downgraded by Barclays with a new price target

      Barclays downgraded Bunge from Overweight to Equal Weight and set a new price target of $95.00 from $115.00 previously

      1/21/25 7:41:13 AM ET
      $BG
      Packaged Foods
      Consumer Staples
    • Bunge downgraded by Citigroup with a new price target

      Citigroup downgraded Bunge from Buy to Neutral and set a new price target of $114.00 from $125.00 previously

      8/1/24 6:22:03 AM ET
      $BG
      Packaged Foods
      Consumer Staples
    • Bunge upgraded by HSBC Securities with a new price target

      HSBC Securities upgraded Bunge from Hold to Buy and set a new price target of $105.00 from $122.00 previously

      2/9/24 6:10:54 AM ET
      $BG
      Packaged Foods
      Consumer Staples

    $BG
    $DICE
    $KDNY
    $QUOT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bunge Schedules Second Quarter 2025 Earnings Release and Conference Call

      Bunge Global SA (NYSE:BG) will announce its results for the quarter ended June 30, 2025, on Wednesday, July 30, 2025, prior to the market opening. The Company's management will also host a conference call at 7 a.m. Central Time to discuss the results. A slide presentation to accompany the discussion will be posted at www.bunge.com. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250709812855/en/BG) will announce its results for the quarter ended June 30, 2025, on Wednesday, July 30, 2025, prior to the market opening.">Bunge Global SA (NYSE:BG) will announce its results for the quarter ended June 30, 2025, on Wednesday, July 30, 2

      7/9/25 7:00:00 AM ET
      $BG
      Packaged Foods
      Consumer Staples
    • Bunge Limited Finance Corp. Announces Expiration and Final Results of Exchange Offers

      Bunge Global SA (NYSE:BG) ("Bunge"), today announced the expiration and final results of the previously announced (A) offers to exchange (each an "Exchange Offer" and, collectively the "Exchange Offers") by its wholly-owned subsidiary, Bunge Limited Finance Corp. ("BLFC"), of any and all outstanding 2.000% Notes due 2026 (the "Existing Viterra 2026 Notes"), 4.900% Notes due 2027 (the "Existing Viterra 2027 Notes"), 3.200% Notes due 2031 (the "Existing Viterra 2031 Notes") and 5.250% Notes due 2032 (the "Existing Viterra 2032 Notes", and together with the Existing Viterra 2026 Notes, the Existing Viterra 2027 Notes, and the Existing Viterra 2031 Notes, collectively, the "Existing Viterra Not

      7/7/25 9:09:00 AM ET
      $BG
      Packaged Foods
      Consumer Staples
    • Bunge and Viterra Complete Merger to Create Premier Global Agribusiness Solutions Company

      Bunge Global SA (NYSE:BG) ("Bunge") today announced the successful closing of its previously announced merger with Viterra Limited ("Viterra"), marking the creation of a premier global agribusiness solutions company for food, feed and fuel. Greg Heckman, Bunge's Chief Executive Officer, said: "Today is a defining moment for our company and our global team as we complete this transformative business combination. I'm grateful to our colleagues whose energy, collaboration and commitment brought us to this milestone. Together, we've formed a stronger organization with enhanced capabilities and expertise to meet the evolving needs of our customers, maximize value for our stakeholders and fulfi

      7/2/25 1:15:00 PM ET
      $BG
      Packaged Foods
      Consumer Staples

    $BG
    $DICE
    $KDNY
    $QUOT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Canada Pension Plan Investment Board claimed ownership of 26,244,732 units of Registered Shares (SEC Form 3)

      3 - Bunge Global SA (0001996862) (Issuer)

      7/8/25 5:48:07 PM ET
      $BG
      Packaged Foods
      Consumer Staples
    • Director Jensen Anne was granted 2,164 shares (SEC Form 4)

      4 - Bunge Global SA (0001996862) (Issuer)

      7/7/25 7:03:37 PM ET
      $BG
      Packaged Foods
      Consumer Staples
    • Director Walt Markus was granted 2,164 shares (SEC Form 4)

      4 - Bunge Global SA (0001996862) (Issuer)

      7/7/25 7:03:27 PM ET
      $BG
      Packaged Foods
      Consumer Staples

    $BG
    $DICE
    $KDNY
    $QUOT
    Financials

    Live finance-specific insights

    See more
    • Bunge Schedules Second Quarter 2025 Earnings Release and Conference Call

      Bunge Global SA (NYSE:BG) will announce its results for the quarter ended June 30, 2025, on Wednesday, July 30, 2025, prior to the market opening. The Company's management will also host a conference call at 7 a.m. Central Time to discuss the results. A slide presentation to accompany the discussion will be posted at www.bunge.com. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250709812855/en/BG) will announce its results for the quarter ended June 30, 2025, on Wednesday, July 30, 2025, prior to the market opening.">Bunge Global SA (NYSE:BG) will announce its results for the quarter ended June 30, 2025, on Wednesday, July 30, 2

      7/9/25 7:00:00 AM ET
      $BG
      Packaged Foods
      Consumer Staples
    • Bunge Reports First Quarter 2025 Results

      Bunge Global SA (NYSE:BG) today reported first quarter 2025 results Q1 GAAP diluted EPS of $1.48 vs. $1.68 in the prior year; $1.81 vs. $3.04 on an adjusted basis excluding certain gains/charges and mark-to-market timing differences Solid performance in Agribusiness driven by Processing, though down from last year Refined and Specialty Oils results reflected a more balanced supply and demand environment, particularly in the U.S. In final stage of regulatory process for Viterra transaction Further strengthened business alignment with our global value chains through agreements to divest regional corn milling and margarine businesses Maintaining adjusted full-year EPS outlook of ap

      5/7/25 6:00:00 AM ET
      $BG
      Packaged Foods
      Consumer Staples
    • Bunge Schedules First Quarter 2025 Earnings Release and Conference Call

      Bunge Global SA (NYSE:BG) will announce its results for the quarter ended March 31, 2025, on Wednesday, May 7, 2025, prior to the market opening. The Company's management will also host a conference call at 7:00 a.m. Central Time to discuss the results. A slide presentation to accompany the discussion will be posted on www.bunge.com. To access the webcast, go to "Events & Presentations" under "News & Events" in the "Investor Center" section of the company's website. Select "Q1 2025 Bunge Global SA Conference Call" and follow the prompts. Please go to the website at least 15 minutes prior to the call to register and download any necessary audio software. To listen to the call, please dial

      4/9/25 7:00:00 AM ET
      $BG
      Packaged Foods
      Consumer Staples

    $BG
    $DICE
    $KDNY
    $QUOT
    Leadership Updates

    Live Leadership Updates

    See more
    • Bunge Announces Approval of Quarterly Dividends and Changes to Board of Directors by Shareholders at 2025 Annual General Meeting

      Shareholders of Bunge Global SA (NYSE:BG) approved a cash dividend in the amount of $2.80 per share, payable in four equal installments of $0.70, at the company's 2025 Annual General Meeting held in Switzerland today ("AGM"). The dividends will be paid as indicated below: Bunge Quarter, Fiscal Year Payment Date Record Date Amount 2nd Quarter, Fiscal Year 2025 June 2, 2025 May 19, 2025 $0.70 3rd Quarter, Fiscal Year 2025 September 2, 2025 August 19, 2025 $0.70 4th Quarter, Fiscal Year 2025 December 1, 2025 November 17, 2025 $0.70 1st Quarter, Fiscal Year 2026 March 3, 2026 February 17, 2026 $0.70 Shareholders also approv

      5/15/25 5:00:00 PM ET
      $BG
      Packaged Foods
      Consumer Staples
    • Chinook Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Updates

      SEATTLE, May 09, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today reported financial results for the first quarter ended March 31, 2023 and provided corporate updates. "During the first quarter of 2023, we continued to advance our pipeline of clinical and preclinical programs for rare, severe chronic kidney diseases. We recently completed full enrollment of the phase 3 ALIGN clinical trial, are on track to initiate the phase 3 BION-1301 IgAN clinical trial mid-year and expect to report topline ALIGN results in the fourth quarter of thi

      5/9/23 4:00:00 PM ET
      $KDNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chinook Therapeutics Announces the Appointment of Robert W. Azelby to its Board of Directors

      SEATTLE, April 13, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the appointment of Robert W. Azelby to its Board of Directors. Mr. Azelby brings more than 20 years of executive leadership and commercial experience in the biopharmaceutical industry to Chinook. "We are thrilled to welcome Bob to Chinook's board of directors as we advance our pipeline through key milestones in 2023 and beyond," said Eric Dobmeier, president and chief executive officer of Chinook Therapeutics. "Bob brings significant industry experience in bu

      4/13/23 8:00:00 AM ET
      $KDNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BG
    $DICE
    $KDNY
    $QUOT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Bunge Limited

      SC 13G/A - Bunge Global SA (0001996862) (Subject)

      11/7/24 12:58:26 PM ET
      $BG
      Packaged Foods
      Consumer Staples
    • Amendment: SEC Form SC 13G/A filed by Bunge Limited

      SC 13G/A - Bunge Global SA (0001996862) (Subject)

      11/6/24 2:13:04 PM ET
      $BG
      Packaged Foods
      Consumer Staples
    • SEC Form SC 13G/A filed by Bunge Limited (Amendment)

      SC 13G/A - Bunge Global SA (0001996862) (Subject)

      3/7/24 12:29:51 PM ET
      $BG
      Packaged Foods
      Consumer Staples